Stoke Therapeutics, Inc.
STOK · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1 | $0 | $0 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 316.3% | -29.2% | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -271.4% | -1,279.1% | -828.8% | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -243.4% | -1,192.5% | -814.7% | – |
| EPS Diluted | -1.65 | -2.38 | -2.6 | -2.34 |
| % Growth | 30.7% | 8.5% | -11.1% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |